PreVu(R) Skin Cholesterol Clinics Rollout Nationally

PreVu(R) Skin Cholesterol Clinics Rollout Nationally 
Over 80 Pharmacies Preparing for Expanded Consumer Testing Across
Canada 
WINNIPEG, MANITOBA -- (Marketwire) -- 02/27/13 -- Miraculins Inc.
(TSX VENTURE:MOM), a medical diagnostic company focused on acquiring,
developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, is pleased to provide the
market with an update on a series of rolling PreVu(R) POC Skin
Cholesterol Testing Clinics that are scheduled to be held across
Canada throughout March and April and into the spring.   
"Over 80 pharmacies under the London Drugs banner in Western Canada
and the PharmaChoice banner in Eastern Canada, are currently
preparing to launch PreVu POC Testing Clinics, in every province
except Quebec, this coming March and April," said Paul Moreau, Vice
President, Sales and Marketing for Miraculins Inc. "The London Drugs
Clinics represent the second stage of PreVu POC Testing expansion
plans through the pharmacy's chain and the PharmaChoice Clinics
represent the leading edge of network expansion into PharmaChoice
pharmacies in Eastern Canada. Expansion news related to the Quebec
pharmacy segment is anticipated at the conclusion of sales and
marketing discussions with interested parties currently underway."   
"The commencement of these extensive PreVu POC Testing Clinics will
also mark the continuation of an expansive public relations campaign
by Miraculins to further raise marketplace awareness about the test
and its benefits. In addition, specially developed educational
programming is being made available to help educate healthcare
professionals, general practitioners and lipid specialists about the
science behind PreVu and the technology's clinical utility and
application," added Moreau.    
A complete list of the London Drugs and PharmaChoice PreVu POC
Testing locations featuring clinics in British Columbia, Alberta,
Saskatchewan, Manitoba, Ontario, Nova Scotia, New Brunswick, Prince
Edward Island, and Newfoundland for this March and April can be
accessed at http://www.prevu.com/PreVu_Clinics.pdf. Additional
locations will continue to be added in both Eastern and Western
Canada in the months that follow, with the expectation that
participating stores will transition to offering PreVu POC testing as
an ongoing risk assessment service available either through walk-up
request or by appointment, as well as through ongoing rotating
clinics. 
About the PreVu Non-Invasive Skin Cholesterol Test  
The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test
is a non-invasive, risk assessment technology designed to measure
skin cholesterol - an important new biomarker in assessing risk of
coronary artery disease ("CAD"). The PreVu(R) POC Test is completely
painless, non-invasive, involves no blood draw or needles, and
requires no overnight fasting. This in vitro diagnostic test is
conducted on the palm of the hand in less than 5 minutes with results
being immediately available, facilitating point of care consultation
and a next steps discussion. Skin cholesterol is the cholesterol that
has been deposited and diffused into tissue, as opposed to freely
circulating in the bloodstream, and the skin contains approximately
11% of all the cholesterol found in the human body, by weight.
Elevated skin cholesterol has been shown in clinical studies to be
strongly associated with significant CAD as measured by treadmill
stress testing and coronary angiography, as well as measured by
testing for coronary calcium, carotid artery thickening, and carotid
artery plaque. The PreVu POC Test does not diagnose the presence or
absence of CAD, but helps to identify patients who may be at higher,
hidden risk for CAD by measuring this new biomarker. For more
information, visit www.prevu.com. 
About Miraculins Inc.  
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive tests for unmet clinical
needs. A significant number of promising diagnostic opportunities
remain un-commercialized because of the sizable gap between the
discovery stage, when research institutions are typically involved,
and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. Miraculins is also
advancing a suite of biomarkers to aid in the early detection of the
devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's
largest diagnostic companies. For more information, visit
www.miraculins.com. 
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to,
 among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.  
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.  
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) is a registered trademark of Miraculins Inc. All Rights
Reserved. 2013. 
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Contacts:
Miraculins Inc.
Paul J. Moreau
Vice President, Sales & Marketing
204-478-5603
204-453-1546 (FAX) 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
 
 
Press spacebar to pause and continue. Press esc to stop.